Literature DB >> 22976499

Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study.

Daniela Di Giuda1, Giovanni Camardese, Anna Rita Bentivoglio, Fabrizio Cocciolillo, Arianna Guidubaldi, Lorella Pucci, Isabella Bruno, Luigi Janiri, Alessandro Giordano, Alfonso Fasano.   

Abstract

PURPOSE: Psychiatric symptoms frequently occur in patients with movement disorders. They are not a mere reaction to chronic disability, but most likely due to a combination of psychosocial factors and biochemical dysfunction underlying the movement disorder. We assessed dopamine transporter (DAT) availability by means of (123)I-FP-CIT SPECT, and motor and psychiatric features in patients with Parkinson's disease, primary dystonia and essential tremor, exploring the association between SPECT findings and symptom severity.
METHODS: Enrolled in the study were 21 patients with Parkinson's disease, 14 patients with primary dystonia and 15 patients with essential tremor. The severity of depression symptoms was assessed using the Hamilton depression rating scale, anxiety levels using the Hamilton anxiety rating scale and hedonic tone impairment using the Snaith-Hamilton pleasure scale. Specific (123)I-FP-CIT binding in the caudate and putamen was calculated based on ROI analysis. The control group included 17 healthy subjects.
RESULTS: As expected, DAT availability was significantly decreased in patients with Parkinson's disease, whereas in essential tremor and dystonia patients it did not differ from that observed in the control group. In Parkinson's disease patients, an inverse correlation between severity of depression symptoms and DAT availability in the left caudate was found (r = -0.63, p = 0.002). In essential tremor patients, levels of anxiety symptoms were inversely correlated with DAT availability in the left caudate (r = -0.69, p = 0.004). In dystonia patients, the severities of both anxiety and depression symptoms were inversely associated with DAT availability in the left putamen (r = -0.71, p = 0.004, and r = -0.75, p = 0.002, respectively). There were no correlations between psychometric scores and (123)I-FP-CIT uptake ratios in healthy subjects.
CONCLUSION: We found association between presynaptic dopaminergic function and affective symptoms in different movement disorders. Interestingly, the inverse correlation was present in each group of patients, supporting the fascinating perspective that common subcortical substrates may be involved in both anxiety and depression dimensions and movement disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22976499     DOI: 10.1007/s00259-012-2232-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  85 in total

1.  Personality traits and brain dopaminergic function in Parkinson's disease.

Authors:  V Kaasinen; E Nurmi; J Bergman; O Eskola; O Solin; P Sonninen; J O Rinne
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

2.  The cerebellum communicates with the basal ganglia.

Authors:  Eiji Hoshi; Léon Tremblay; Jean Féger; Peter L Carras; Peter L Strick
Journal:  Nat Neurosci       Date:  2005-10-02       Impact factor: 24.884

3.  Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson's disease.

Authors:  Karsten Witt; Christine Daniels; Jan Herzog; Delia Lorenz; Jens Volkmann; Julia Reiff; Maximilian Mehdorn; Günther Deuschl; Paul Krack
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2006       Impact factor: 2.198

4.  Left-sided Parkinson's disease is associated with greater anxiety and depression.

Authors:  S Fleminger
Journal:  Psychol Med       Date:  1991-08       Impact factor: 7.723

5.  A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale.

Authors:  R P Snaith; M Hamilton; S Morley; A Humayan; D Hargreaves; P Trigwell
Journal:  Br J Psychiatry       Date:  1995-07       Impact factor: 9.319

6.  Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

Authors:  R Pahwa; M A Stacy; S A Factor; K E Lyons; F Stocchi; B P Hersh; L W Elmer; D D Truong; N L Earl
Journal:  Neurology       Date:  2007-04-03       Impact factor: 9.910

Review 7.  Depression in neurological disorders: an update.

Authors:  Hugh Rickards
Journal:  Curr Opin Psychiatry       Date:  2006-05       Impact factor: 4.741

8.  123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

Authors:  A Antonini; R Benti; R De Notaris; S Tesei; A Zecchinelli; G Sacilotto; N Meucci; M Canesi; C Mariani; G Pezzoli; P Gerundini
Journal:  Neurol Sci       Date:  2003-10       Impact factor: 3.307

9.  Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder.

Authors:  Franklin R Schneier; Anissa Abi-Dargham; Diana Martinez; Mark Slifstein; Dah-Ren Hwang; Michael R Liebowitz; Marc Laruelle
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

10.  Abnormal striatal and thalamic dopamine neurotransmission: Genotype-related features of dystonia.

Authors:  M Carbon; M Niethammer; S Peng; D Raymond; V Dhawan; T Chaly; Y Ma; S Bressman; D Eidelberg
Journal:  Neurology       Date:  2009-06-16       Impact factor: 9.910

View more
  19 in total

1.  Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease.

Authors:  Valtteri Kaasinen; Maija Kinos; Juho Joutsa; Marko Seppänen; Tommi Noponen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-28       Impact factor: 9.236

Review 2.  Non-motor features of Parkinson disease.

Authors:  Anthony H V Schapira; K Ray Chaudhuri; Peter Jenner
Journal:  Nat Rev Neurosci       Date:  2017-06-08       Impact factor: 34.870

Review 3.  Linking Essential Tremor to the Cerebellum-Neuroimaging Evidence.

Authors:  Antonio Cerasa; Aldo Quattrone
Journal:  Cerebellum       Date:  2016-06       Impact factor: 3.847

Review 4.  Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.

Authors:  Stéphane Prange; Hélène Klinger; Chloé Laurencin; Teodor Danaila; Stéphane Thobois
Journal:  Drugs Aging       Date:  2022-06-16       Impact factor: 4.271

5.  Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson's disease without dementia.

Authors:  Yoon-Sang Oh; Jean Hee Kim; Sang-Won Yoo; Eo-Jin Hwang; Chul Hyoung Lyoo; Kwang-Soo Lee; Joong-Seok Kim
Journal:  Neurol Sci       Date:  2020-10-31       Impact factor: 3.307

6.  Comment on Di Giuda et al.: Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study.

Authors:  Roberto Erro; Sabina Pappatà; Paolo Barone; Maria Teresa Pellecchia
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-07       Impact factor: 9.236

7.  Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT study: reply to comment by Erro et al.

Authors:  Daniela Di Giuda; Giovanni Camardese; Fabrizio Cocciolillo; Alfonso Fasano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-07       Impact factor: 9.236

8.  Altered striatal circuits underlie characteristic personality traits in Parkinson's disease.

Authors:  Toru Ishii; Nobukatsu Sawamoto; Hayato Tabu; Hidekazu Kawashima; Tomohisa Okada; Kaori Togashi; Ryosuke Takahashi; Hidenao Fukuyama
Journal:  J Neurol       Date:  2016-06-22       Impact factor: 4.849

9.  Antidepressant treatment effects on dopamine transporter availability in patients with major depression: a prospective 123I-FP-CIT SPECT imaging genetic study.

Authors:  Sabine Hellwig; Lars Frings; Annette Masuch; Werner Vach; Katharina Domschke; Claus Normann; Philipp T Meyer
Journal:  J Neural Transm (Vienna)       Date:  2018-02-23       Impact factor: 3.575

Review 10.  Neuroimaging essentials in essential tremor: a systematic review.

Authors:  Sarvi Sharifi; Aart J Nederveen; Jan Booij; Anne-Fleur van Rootselaar
Journal:  Neuroimage Clin       Date:  2014-05-09       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.